Landos Biopharma — Merger or Acquisition (March 2024)
12 slides from Landos Biopharma's merger presentation, Mar 25, 2024
Slide 1: All Hands Meeting March 25, 2024
All Hands Meeting March 25, 2024
Slide 2: Forward-looking statements
Some statements in this presentation, and documents referred to in this presentation, are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It In connection with the proposed transaction, Landos will be filing relevant documents with the SEC, including preliminary and definitive proxy statements on Schedule 14A relating to the proposed transaction. The definitive proxy statement will be sent to L
Slide 4: Landos to be Acquired by AbbVie: Deal Summary
Landos will be acquired for ~$137.5 million in the aggregate1 or $20.42 per share Potential for an additional future payment of up to $75 million in the aggregate, or $11.14 per share, upon achievement of a clinical development milestone Combination of the upfront and potential future payment repres
Slide 5: What You Can Expect Going Forward
What You Can Expect Going Forward Separate & independent companies Continued focus on NX-13 & NEXUS Pre-integration planning Strict gun jumping rules Expected during Q2 2024 Integration work begins *We are here*
Slide 6: Pre-Integration Planning: Don't Jump the Gun!
Continue to operate separately & independently Neither Landos nor AbbVie may exercise control – or give the appearance of exercising control – over the other, or the employees of the other Pre-integration planning is good; Implementing integration plans prior to close is not Pre-integration planning
Slide 7: Your continued commitment is critical to advance our work
Your continued commitment is critical to advance the critical work we have in process Patients & NEXUS partners are counting on us In recognition of the important role you play at Landos, and provided that you remain employed with the Company through closing, you may be eligible for the following: V
Slide 8: Helpful Hints in Times of Change
Create focus for you and your team Be a positive influence & constant energizer Ask for more information and help proactively Empathize, but don’t commiserate Recognize cues from your colleagues and yourself Control the “controllables” Helpful Hints in Times of Change
Slide 9: Call to Action: Continued focus on NX-13 & NEXUS
Continued focus on Priority 1, 2 & 3: NX-13 & NEXUS Call to Action
Slide 10: My Commitment to You
Full transparency & open communication, always! Information We won’t have all the answers today, but will get you answers you need in time Going forward, submit any new questions to Kyle Evans at kyle@landosbiopharma.com Additional resources An employee FAQ, as well as additional materials, as neede
Slide 11: Q&A
Q&A
Slide 12: All Hands Meeting March 25, 2024
All Hands Meeting March 25, 2024 The following letter was sent to certain of the Company’s vendors and strategic partners on March 25, 2024 : Dear [Vendor/Strategic Partner], As you may have already heard, Landos Biopharma will be acquired by AbbVie at a price of $20.42 per share in cash upon closin
Landos Biopharma — Merger or Acquisition (March 2024) on 6ix